Free Access: Please Log In
This content is completely free—but you need to be logged in to read the full article. If you already have an account, please log in below. Otherwise, register for free to unlock instant access.
References (6)
- Wermuth HR, Badri T, Takov V. Montelukast. StatPearls Publishing; 2022.
- Ducharme FM, Bénard B, Vinet B, et al. Neuropsychiatric adverse drug reactions in children initiated on montelukast in real-life practice. Eur Respir J. 2017;50(5):1702135. PubMed CrossRef
- Clarridge K, Chin S, Eworuke E, et al. A boxed warning for montelukast: the FDA perspective. J Allergy Clin Immunol Pract. 2021;9(7):2638–2641. PubMed CrossRef
- Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245. PubMed CrossRef
- Marques CF, Marques MM, Justino GC. The mechanisms underlying montelukast’s neuropsychiatric effects-new insights from a combined metabolic and multiomics approach. Life Sci. 2022;310:121056. PubMed CrossRef
- Umetsu R, Tanaka M, Nakayama Y, et al. Neuropsychiatric adverse events of montelukast: an analysis of real-world datasets and drug−gene interaction network. Front Pharmacol. 2021;12:764279. PubMed CrossRef
Buy PDF for $40
Please sign in or purchase this PDF for $40.
Save
Share
Cite
